AHR and melanoma: Our hypothesis is also further reinforced by published reports in BRAFV600E melanoma that showed activation of the SRC pathway by Aryl hydrocarbon Receptor (AhR) promotes the acquisition of an invasive and aggressive phenotype resistant to front-line BRAF inhibitors [34].